COVID-19 is associated with significant cardiovascular complications, both from the viral infection itself and as adverse effects of treatments, necessitating careful cardiological monitoring.
Clinicians should remain alert to CV sequelae and COVID-19 drug interactions; leaves open validation of current cardioprotective recommendations.
Based on the literature data, we present current literature information about frequency, main spectrum, and prognostic value of cardiovascular complications of the SARS-CoV-2 infection. We have highlighted in detail the variants of cardiovascular disorders in the case of patients with SARS-CoV-2 infection caused by concomitant diseases of hypertension, acute coronary syndrome, myocardial infarction, arrhythmias, virus-associated myocarditis, and heart failure. We have described the adverse cardiovascular effects of medicines of different groups used to treat COVID-19 disease and possible medical interactions. We have summarized some current recommendations on cardiotonic and cardioprotective therapy in the case of patients with cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Kovalevskaiia et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: